Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer

CompletedOBSERVATIONAL
Enrollment

605

Participants

Timeline

Start Date

May 2, 2021

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Fallopian Tube Cancer
Trial Locations (24)

Unknown

Research Site, Kuwait City

Research Site, Muscat

Research Site, Doha

Research Site, Balashikha

Research Site, Istra Settlement

Research Site, Kolomna

Research Site, Arkhangelsk

Research Site, Belgorod

Research Site, Chelyabinsk

Research Site, Irkutsk

Research Site, Krasnoyarsk

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Rostov-on-Don

Research Site, Saint Petersburg

Research Site, Tomsk

Research Site, Tula

Research Site, Tyumen

Research Site, Ufa

Research Site, Yaroslavl

Research Site, Yuzhno-Sakhalinsk

Research Site, Jeddah

Research Site, Mecca

Research Site, Alain

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY